Scandinavian ChemoTech increases the value of its order book
After Scandinavian ChemoTech AB (publ) today received a signed electronic copy of its CE certificate, the Company is now increasing its order book by an additional approximately kSEK 7.
Although we have already informed about the Company's successful CE marking of the Company's innovation for cancer treatments, we have waited to increase the value of our order book until we have received a signed CE certificate. After receiving an electronic copy of the signed certificate, ChemoTech is now increasing its order book by approximately kSEK 7 for orders intended for Vietnam, Singapore and Ukraine.
“It feels good to be able to start registration and carrying out deliveries to these distributors, whom has been loyal to us during the CE marking process. Now we need to use the time well until the COVID-19 pandemic ends so that we can create successful launches in these countries.”- says Mohan Frick, CEO of Scandinavian ChemoTech
For more information, please contact:
Mohan Frick, CEO
Phone: +46 (0)10-218 93 00
Certified Adviser: Erik Penser Bank, Tel: +46 8 463 80 00, E-mail: certifiedadviser@penser.se
Scandinavian ChemoTech AB (publ)
ChemoTech is a Swedish medical technology company based in Lund that has developed a patented technology platform to offer cancer patients access to a new treatment alternative, Tumour Specific Electroporation™ (TSE), available for treatment of both humans and animals. There are a large number of cancer patients whose tumours for various reasons cannot be treated by conventional methods but where TSE can be a solution. Therefore, the company continuously evaluates new opportunities and areas of application for the technology. ChemoTech's shares (CMOTEC B) are listed on Nasdaq First North Growth Market in Stockholm and Erik Penser Bank is the company's Certified Adviser. Read more at: www.chemotech.se.